Lenvatinib

Generic Name: Lenvatinib

Brand Names: Lenvima 10, Kisplyx, Lenvima

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉ClN_₄O_₄

CAS Number: 417716-92-8

Unique Ingredient Identifier: EE083865G2

Background: Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...

Indication: Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions: Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)

Associated Therapies: -

Clinical Trials

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Phase 2

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: Hepatic arterial infusion chemotherapy
Drug: Folfox Protocol
Drug: Lenvatinib
Drug: PD-1 antibody

First Posted Date: 2019-01-14

Last Posted Date: 2019-05-06

Lead Sponsor: Sun Yat-sen University

Registration Number: NCT03803254

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Kaiping Central Hospital, Kaiping, Guangdong, China
🇨🇳
Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Phase 2

Withdrawn

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Lenvatinib

First Posted Date: 2019-01-11

Last Posted Date: 2020-05-21

Lead Sponsor: Sun Yat-sen University

Registration Number: NCT03801499

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Phase 2

Completed

Conditions: Advanced Solid Tumors
Triple Negative Breast Cancer
Ovarian Cancer
Gastric Cancer
Colorectal Cancer
Glioblastoma
Biliary Tract Cancers
Pancreatic Cancer

Interventions: Drug: Lenvatinib
Biological: Pembrolizumab

First Posted Date: 2019-01-09

Last Posted Date: 2024-11-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 603

Registration Number: NCT03797326

Locations: 🇺🇸
Mary Crowley Cancer Research Centers - Medical City Hospital ( Site 0049), Dallas, Texas, United States
🇦🇺
Sir Charles Gairdner Hospital ( Site 0903), Nedlands, Western Australia, Australia
🇺🇸
City of Hope ( Site 0002), Duarte, California, United States

and more 85 locations

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Phase 3

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: TACE
Drug: Lenvatinib
Drug: PD-1 antibody
Drug: TACE Drug Protocol

First Posted Date: 2019-01-03

Last Posted Date: 2019-05-02

Lead Sponsor: Sun Yat-sen University

Registration Number: NCT03791918

Locations: 🇨🇳
Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China
🇨🇳
Kaiping Central Hospital, Kaiping, Guangdong, China
🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Lenvatinib Plus PD-1 Antibody for Unresectable ICC

Phase 2

Suspended

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Lenvatinib
Drug: PD-1 antibody

First Posted Date: 2018-12-19

Last Posted Date: 2019-01-28

Lead Sponsor: Shi Ming

Target Recruit Count: 25

Registration Number: NCT03779100

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Phase 2

Completed

Conditions: Advanced Melanoma

Interventions: Drug: lenvatinib
Biological: pembrolizumab

First Posted Date: 2018-12-14

Last Posted Date: 2024-10-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 103

Registration Number: NCT03776136

Locations: 🇺🇸
John Wayne Cancer Institute ( Site 0301), Santa Monica, California, United States
🇺🇸
Advocate Medical Group-Park Ridge ( Site 0313), Park Ridge, Illinois, United States
🇺🇸
Southeast Nebraska Cancer Center ( Site 0316), Lincoln, Nebraska, United States

and more 20 locations

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Phase 2

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Lenvatinib
Drug: PD-1 antibody

First Posted Date: 2018-12-14

Last Posted Date: 2019-05-06

Lead Sponsor: Shi Ming

Registration Number: NCT03775707

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC

Phase 3

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Lenvatinib
Drug: Sorafenib
Procedure: Hepatic arterial infusion chemotherapy

First Posted Date: 2018-12-13

Last Posted Date: 2019-01-03

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 250

Registration Number: NCT03775395

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC

Phase 2

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Lenvatinib
Drug: PD-1 antibody

First Posted Date: 2018-11-19

Last Posted Date: 2019-04-17

Lead Sponsor: Sun Yat-sen University

Registration Number: NCT03746249

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Phase 3

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Lenvatinib
Drug: PD-1 antibody
Drug: Placebo

First Posted Date: 2018-11-16

Last Posted Date: 2019-05-02

Lead Sponsor: Sun Yat-sen University

Registration Number: NCT03744247

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy